Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | IBI3003 |
Synonyms | |
Therapy Description |
Limited information is currently available on IBI3003, a putative T-cell engager therapy targeting GPRC5D and BCMA (Oct 2023). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
IBI3003 | IBI-3003|IBI 3003 | Limited information is currently available on IBI3003, a putative T-cell engager therapy targeting GPRC5D and BCMA (Oct 2023). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06083207 | Phase Ib/II | IBI3003 | A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma | Recruiting | AUS | 1 |